CDER Planning Multiple Generics Guidances in 2021, Agenda Reveals

The FDA’s Center for Drug Evaluation and Research (CDER) has released its list of planned new and revised guidances for calendar year 2021, an agenda that includes a large number of generic drug-related topics.
Source: Drug GMP Report